Results 61 to 70 of about 3,980,763 (249)

Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials

, 2004
BACKGROUND: A European (EU) and a North American (NA) placebo-controlled study with interferon beta-1b (IFNB-1b) in secondary progressive multiple sclerosis (SPMS) showed divergent results with regard to their primary outcome of sustained Expanded ...
BOARD, POLMAN C, WEINSHENKER B, THOMPSON AJ, BECKMANN K, MULTIPLE SCLEROSIS TRIAL STEERING COMMITTEE AND INDEPENDENT ADVISORY BOARD, DAHLKE F, NORTH AMERICAN NA SPMS INTERFERON BETA B. IN SECONDARY PROGRESSIVE, MCFARLAND H, EUROPEAN EU SPMS INTERFERON BETA B. IN SECONDARY, POZZILLI, Carlo, KAPPOS L, PROGRESSIVE MULTIPLE SCLEROSIS TRIAL STEERING COMMITTEE AND INDEPENDENT ADVISORY   +12 more
core  

Qualitative consultation with young people in the City of Glasgow on sexual health and relationships: final report November 2006

, 2006
Progressive undertook research on behalf of Glasgow’s Young People’s Sexual Health Steering Group to gain an understanding of the opinions and attitudes that 13 to 19 year olds in the city have towards sexual health and ...
Progressive Partnership Ltd
core   +1 more source

Editorial: Measuring progression in Multiple Sclerosis: Progressing beyond the ordinary

Frontiers in Human Neuroscience, 2022
Carynn Koch, Francesca Bagnato, Francesca Bagnato, Cornelia Laule, Cornelia Laule, Cornelia Laule, Cornelia Laule, Susan A. Gauthier   +7 more
doaj   +1 more source

Progressive Diffuse Osteonecrosis in a Patient with Secondary Hemophagocytic Lymphohistiocytosis

Case Reports in Radiology, 2015
This is a case report with serial imaging showing progression of diffuse osteonecrosis in a patient after a diagnosis of secondary hemophagocytic lymphohistiocytosis (HLH).
Takashi Takahashi, Jeffrey Rykken
doaj   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

Molecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang, Hyung Seok Kim, Geum Ok Baek, Moon Gyeong Yoon, Su In Lee, Jee‐Yeong Jeong, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun   +9 more
wiley   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

N.A.P.A. Newsletter; New Africa Progressive Alliance Newsletter, Supplement to The Bantu World; Bantu World

, 2015
New Africa Progressive Alliance Newsletter no. 6 (supplement to The Bantu World).

core  

Paclitaxel induces NM2‐dependent cellular contraction through GEF‐H1 dissociation from microtubules and RhoA/ROCK activation in cancer cells

Molecular Oncology, EarlyView.
Taxanes are widely used chemotherapeutics whose effects on cellular mechanics remain poorly understood. We show that paclitaxel induces rapid cellular contraction by promoting GEF‐H1 dissociation from microtubules and non‐muscle myosin II activation through RhoA/ROCK.
Gloria Asensio‐Juárez, Rafael Pérez‐Díaz, Hugo Ramos‐Solano, Marina Garrido‐Casado, Vanessa C. Talayero, Miguel Vicente‐Manzanares   +5 more
wiley   +1 more source